Literature DB >> 32605679

Registry-based trials: a potential model for cost savings?

Brett R Anderson1, Evelyn G Gotlieb2, Kevin Hill3, Kimberly E McHugh4, Mark A Scheurer4, Carlos M Mery5, Glenn J Pelletier6, Jonathan R Kaltman7, Owen J White8, Felicia L Trachtenberg9, Danielle Hollenbeck-Pringle9, Brian W McCrindle10, Donna M Sylvester11, Aaron W Eckhauser12, Sara K Pasquali13, Jeffery B Anderson14, Marcus S Schamberger15, Subhadra Shashidharan16, Jeffrey P Jacobs17, Marshall L Jacobs18, Marko Boskovski19, Jane W Newburger20,21, Meena Nathan21,22.   

Abstract

BACKGROUND/AIMS: Registry-based trials have emerged as a potentially cost-saving study methodology. Early estimates of cost savings, however, conflated the benefits associated with registry utilisation and those associated with other aspects of pragmatic trial designs, which might not all be as broadly applicable. In this study, we sought to build a practical tool that investigators could use across disciplines to estimate the ranges of potential cost differences associated with implementing registry-based trials versus standard clinical trials.
METHODS: We built simulation Markov models to compare unique costs associated with data acquisition, cleaning, and linkage under a registry-based trial design versus a standard clinical trial. We conducted one-way, two-way, and probabilistic sensitivity analyses, varying study characteristics over broad ranges, to determine thresholds at which investigators might optimally select each trial design.
RESULTS: Registry-based trials were more cost effective than standard clinical trials 98.6% of the time. Data-related cost savings ranged from $4300 to $600,000 with variation in study characteristics. Cost differences were most reactive to the number of patients in a study, the number of data elements per patient available in a registry, and the speed with which research coordinators could manually abstract data. Registry incorporation resulted in cost savings when as few as 3768 independent data elements were available and when manual data abstraction took as little as 3.4 seconds per data field.
CONCLUSIONS: Registries offer important resources for investigators. When available, their broad incorporation may help the scientific community reduce the costs of clinical investigation. We offer here a practical tool for investigators to assess potential costs savings.

Entities:  

Keywords:  Registry-based trial; cost savings; pragmatic trial; trial design

Mesh:

Year:  2020        PMID: 32605679      PMCID: PMC7682727          DOI: 10.1017/S1047951120001018

Source DB:  PubMed          Journal:  Cardiol Young        ISSN: 1047-9511            Impact factor:   1.093


  23 in total

1.  Using cost-effectiveness analysis to improve the efficiency of allocating funds to clinical trials.

Authors:  A S Detsky
Journal:  Stat Med       Date:  1990 Jan-Feb       Impact factor: 2.373

2.  The randomized registry trial--the next disruptive technology in clinical research?

Authors:  Michael S Lauer; Ralph B D'Agostino
Journal:  N Engl J Med       Date:  2013-08-31       Impact factor: 91.245

3.  Key cost drivers of pharmaceutical clinical trials in the United States.

Authors:  Aylin Sertkaya; Hui-Hsing Wong; Amber Jessup; Trinidad Beleche
Journal:  Clin Trials       Date:  2016-02-08       Impact factor: 2.486

4.  Rationale and design of the STeroids to REduce Systemic inflammation after infant heart Surgery (STRESS) trial.

Authors:  Kevin D Hill; H Scott Baldwin; David P Bichel; Ryan J Butts; Reid C Chamberlain; Alicia M Ellis; Eric M Graham; Jesse Hickerson; Christoph P Hornik; Jeffrey P Jacobs; Marshall L Jacobs; Robert Db Jaquiss; Prince J Kannankeril; Sean M O'Brien; Rachel Torok; Joseph W Turek; Jennifer S Li
Journal:  Am Heart J       Date:  2019-12-09       Impact factor: 4.749

5.  The future of cardiovascular clinical research: informatics, clinical investigators, and community engagement.

Authors:  Robert M Califf; Iain Sanderson; Marie Lynn Miranda
Journal:  JAMA       Date:  2012-11-07       Impact factor: 56.272

Review 6.  Registry-based randomized controlled trials- what are the advantages, challenges, and areas for future research?

Authors:  Guowei Li; Tolulope T Sajobi; Bijoy K Menon; Lawrence Korngut; Mark Lowerison; Matthew James; Stephen B Wilton; Tyler Williamson; Stephanie Gill; Lauren L Drogos; Eric E Smith; Sunita Vohra; Michael D Hill; Lehana Thabane
Journal:  J Clin Epidemiol       Date:  2016-08-20       Impact factor: 6.437

7.  Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials.

Authors:  Benjamin Carlisle; Jonathan Kimmelman; Tim Ramsay; Nathalie MacKinnon
Journal:  Clin Trials       Date:  2014-12-04       Impact factor: 2.486

8.  Evaluating various areas of process improvement in an effort to improve clinical research: discussions from the 2012 Clinical Translational Science Award (CTSA) Clinical Research Management workshop.

Authors:  Jane E Strasser; Philip A Cola; Daniel Rosenblum
Journal:  Clin Transl Sci       Date:  2013-04-19       Impact factor: 4.689

9.  Targeted versus universal decolonization to prevent ICU infection.

Authors:  Susan S Huang; Edward Septimus; Ken Kleinman; Julia Moody; Jason Hickok; Taliser R Avery; Julie Lankiewicz; Adrijana Gombosev; Leah Terpstra; Fallon Hartford; Mary K Hayden; John A Jernigan; Robert A Weinstein; Victoria J Fraser; Katherine Haffenreffer; Eric Cui; Rebecca E Kaganov; Karen Lolans; Jonathan B Perlin; Richard Platt
Journal:  N Engl J Med       Date:  2013-05-29       Impact factor: 91.245

10.  Reducing the confusion and controversies around pragmatic trials: using the Cardiovascular Health Awareness Program (CHAP) trial as an illustrative example.

Authors:  Lehana Thabane; Janusz Kaczorowski; Lisa Dolovich; Larry W Chambers; Lawrence Mbuagbaw
Journal:  Trials       Date:  2015-09-02       Impact factor: 2.279

View more
  1 in total

Review 1.  Cardiac Registries During the COVID-19 Pandemic: Lessons Learned.

Authors:  Jyotpal Singh; Michael-Roy R Durr; Elena Deptuch; Sabiha Sultana; Neha Mehta; Santiago Garcia; Timothy D Henry; Payam Dehghani
Journal:  Curr Cardiol Rep       Date:  2022-04-05       Impact factor: 3.955

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.